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A B S T R A C T
Aims: UDP-sugars can act as extracellular signalling molecules, but relatively little is known about their car-
diovascular actions. The P2Y14 receptor is a Gi/o-coupled receptor which is activated by UDP-glucose and related
sugar nucleotides. In this study we sought to investigate whether P2Y14 receptors are functionally expressed in
the porcine coronary artery using a selective P2Y14 receptor agonist, MRS2690, and a novel selective P2Y14
receptor antagonist, PPTN (4,7-disubstituted naphthoic acid derivative).
Methods and results: Isometric tension recordings were used to evaluate the eﬀects of UDP-sugars in porcine
isolated coronary artery segments. The eﬀects of the P2 receptor antagonists suramin and PPADS, the P2Y14
receptor antagonist PPTN, and the P2Y6 receptor antagonist MRS2578, were investigated. Measurement of
vasodilator-stimulated phosphoprotein (VASP) phosphorylation using ﬂow cytometry was used to assess changes
in cAMP levels. UDP-glucose, UDP-glucuronic acid UDP-N-acetylglucosamine (P2Y14 receptor agonists), elicited
concentration-dependent contractions of the porcine coronary artery. MRS2690 was a more potent vasocon-
strictor than the UDP-sugars. Concentration dependent contractile responses to MRS2690 and UDP-sugars were
enhanced in the presence of forskolin (activator of cAMP), where the level of basal tone was maintained by
addition of U46619, a thromboxane A2 mimetic. Contractile responses to MRS2690 were blocked by PPTN, but
not by MRS2578. Contractile responses to UDP-glucose were also attenuated by PPTN and suramin, but not by
MRS2578. Forskolin-induced VASP-phosphorylation was reduced in porcine coronary arteries exposed to UDP-
glucose and MRS2690, consistent with P2Y14 receptor coupling to Gi/o proteins and inhibition of adenylyl cy-
clase activity.
Conclusions: Our data support a role of UDP-sugars as extracellular signalling molecules and show for the ﬁrst
time that they mediate contraction of porcine coronary arteries via P2Y14 receptors.
1. Introduction
Cellular release of purine nucleotides, including UTP and ATP, is
promoted by stimuli including hypoxia and inﬂammation leading to
activation of cell-surface P2 receptors [8]. UDP-glucose can also be
released from cells to act as an extracellular signalling molecule
[32,35,36]. In preliminary studies we showed that UDP-glucose causes
constriction of the porcine coronary artery [1–3]. Excessive contraction
of the coronary circulation following hypoxic or inﬂammatory release
of UDP-glucose would exacerbate the detrimental eﬀects of these in-
sults. This led us to investigate the hypothesis that the P2Y14 receptor, a
receptor for UDP-glucose and UDP, is expressed in, and mediates the
vasomotor role of UDP-sugars in the porcine coronary vasculature.
Identiﬁcation of the receptor(s) involved in contractile responses to
UDP-sugars may have therapeutic potential in ischaemic heart disease.
P2Y receptors are G protein-coupled receptors activated by purine,
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pyrimidine and sugar nucleotides. There are eight members of the P2Y
family, namely P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14
receptors, with the P2Y14 receptor being the most recently described
[4,9]. The P2Y14 receptor is a Gi/o protein-coupled receptor activated
by UDP-sugars including UDP-glucose, UDP-galactose, UDP-glucuronic
acid, and UDP-N-acetylglucosamine [4,5,16,17,23,44–46]. The P2Y14
receptor is also activated by UDP, and by MRS2690, a more selective
agonist that has a 7-fold greater potency at the P2Y14 receptor than
UDP-glucose [31]. Quantitative analysis has revealed that the P2Y14
protein is expressed in many regions including the brain, adipose tissue,
lung, spleen, heart and certain immune and inﬂammatory cells [9].
There is evidence for the expression of P2Y14 receptor transcript and
protein in vascular smooth muscle cells [5,19,38], but relatively little is
known about the functional expression of this receptor in the cardio-
vascular system. Until recently, the lack of availability of P2Y14 re-
ceptor antagonists made it diﬃcult to determine a role for the P2Y14
receptor. A novel non-nucleotide compound, 4-((piperidin-4-yl)-
phenyl)-7-(4-(triﬂuoromethyl)-phenyl)-2-naphthoic acid (PPTN), was
reported as a high-aﬃnity competitive antagonist at the P2Y14 receptor
[43]. PPTN inhibited UDP-glucose and MRS2690 mediated mast cell
degranulation, and UDP-glucose mediated chemotaxis of neutrophils
[6,16,17]. We recently used PPTN to show, for the ﬁrst time, that UDP-
glucose mediates vasoconstriction through activation of P2Y14 re-
ceptors in porcine pancreatic arteries [5]. UDP-glucose mediates con-
traction in mouse coronary arteries, and the response was retained in
P2Y2 knockouts, however since neither a P2Y14 selective agonist nor
antagonist were employed the identity of the receptor involved requires
conﬁrmation [21]. The aims of the current study were to determine
whether UDP-sugars can modulate contractility of the porcine coronary
artery and to characterize the P2 receptor(s) involved.
Since the P2Y14 receptor is Gi/o protein-coupled, this makes its in-
vestigation diﬃcult in isolated tissues where cAMP levels are normally
low. Accordingly, we used forskolin to stimulate adenylyl cyclase and
raise cAMP levels, a method described by us [5] and others [42] pre-
viously to investigate vascular Gi/o protein-coupled receptors, and on
this background we were able to investigate the pharmacology of the
responses to UDP-glucose and other P2Y14 receptor agonists in the
porcine coronary artery. In this study we report the functional expres-
sion of a contractile P2Y14 receptor sensitive to UDP-sugars in the
porcine coronary artery. The contractile response was mimicked by the
selective P2Y14 agonist, MRS2690, and the response was blocked by the
selective P2Y14 receptor antagonist PPTN. Measurement of VASP
phosphorylation, and of contractile responses in the presence of for-
skolin, indicated that UDP-glucose inhibits cAMP levels, consistent with
the known Gi/o protein-coupling of the P2Y14 receptor.
2. Methods
2.1. Tissue preparation
Hearts were obtained from pigs (either sex, ~6 months old,
weight ~ 50 kg) and were transported on ice from a local abattoir. The
size and arterial system of the porcine heart are very similar to that of
humans [49]. Porcine left circumﬂex coronary arteries were dissected
out and stored overnight at 4 °C in oxygenated (95% O2, 5% CO2)
Krebs-Henseleit buﬀer (mM): sodium chloride 118; potassium chloride
4.8; magnesium sulphate 1.1; sodium hydrogen carbonate 25; po-
tassium hydrogen phosphate 1.2; glucose 12; calcium chloride 1.25. A
ﬁne dissection was carried out the following day. Four adjacent 5 mm
ring segments were cut from each vessel and mounted onto wires for
isometric tension recording (Grass FT03 transducers) in warmed (37 °C)
and gassed (95% O2, 5% CO2) Krebs-Henseleit buﬀer in organ baths. In
some arteries the endothelium was removed by gentle rolling of the
segment with ﬁne-tipped forceps inserted into the lumen [41]. The
success of the treatment was evaluated by testing responsiveness to an
endothelium-dependent vasodilator, substance P.
2.2. Responses in the porcine coronary artery
Rings were put under an initial tension of 10 g [41] and left for
~45 min to equilibrate, after which viability was assessed by eliciting
contractions with 60 mM KCl. After washout and equilibration (30 min)
cumulative concentration response curves to UDP-glucose (0.1 μM-
1 mM), MRS2690 (1 nM-10 μM), UDP-glucuronic acid (0.1 μM-1 mM),
and UDP-N-acetylglucosamine (0.1 μM-1 mM) were constructed at
basal tone.
2.3. Forskolin elevation of cAMP
In some experiments, arteries were preconstricted with U46619
(5–10 nM), a thromboxane A2 mimetic, to elicit contraction of 35–75%
of that to KCl. Forskolin (0.1 μM; activates adenylyl cyclase) was used
to reverse the U46619-mediated contraction. The combination of for-
skolin and U46619 has previously been used to uncover α2-adreno-
ceptor-mediated contractions in porcine ear artery [42]. When vessels
had reached a stable tone (30–45 min), cumulative-concentration re-
sponse curves to UDP-glucose, MRS2690, UDP-glucuronic acid and
UDP-N-acetylglucosamine were constructed. In separate experiments,
PPTN (1 μM) was added 10 min prior to addition of U46619. Cumula-
tive concentration-response curves to UDP-glucose, MRS2690 and UTP
were constructed in the absence and presence of PPTN (1 μM). The
eﬀects of MRS2578 (10 μM, a P2Y6 receptor antagonist), and the P2
receptor antagonists PPADS (10 μM) and suramin (100 μM), were also
investigated. In some experiments sodium nitroprusside (0.1 μM; acti-
vates guanylyl cyclase) was used instead of forskolin, together with
U46619, to investigate eﬀects on contractility to UDP-glucose. In some
experiments UDP-glucose was treated with apyrase (5 U/ml, 30 min)
before use and apyrase (5 U/ml) was also added to the organ baths
prior to U46619 and forskolin additions.
2.4. VASP phosphorylation assay
Porcine coronary arteries were set up in organ baths as described
above. After addition of U46619 (5–10 nM) and forskolin (0.1 μM),
vessels were left to relax to basal tone. These were control vessels,
which were paired with vessels where either 100 μM or 1 mM UDP-
glucose, or 10 μMMRS2690, were added in the absence and presence of
PPTN (1 μM). After the contractions had reached a maximum, vessels
were removed, put into lysis buﬀer, and frozen in dry ice. Tissues were
homogenized and the supernatant was separated by centrifugation
(3000 RCF, 10 min). VASP-phosphorylation in the tissues was measured
by ﬂow cytometry using a cytometric bead assay where VASP in the
samples was captured onto beads using monoclonal anti-VASP (IE273)
followed by detection using FITC conjugated anti-VASP (5C6 anti-VASP
pSer 157, Acris Antibodies, Germany) [27].
2.5. Preparation of platelets
Venous blood was obtained from 7 healthy volunteers (from School
of Life Sciences, University of Nottingham). Ethics was approved by
Thrombosis and Haemostasis Research Group, University of
Nottingham. Blood samples from healthy volunteers were taken in ac-
cordance with local ethical permission and the declaration of Helsinki.
Blood was immediately put into collecting tubes containing EDTA
(4 mM) to prevent blood clotting. For platelet preparation, platelet rich
plasma was obtained by centrifugation at 1100 RPM (15 min) followed
by a 2000 RPM (20 min) centrifugation step to obtain a platelet pellet.
Platelets were resuspended in sterile saline solution (0.9% sodium
chloride) before centrifuging at 1600 RMP (15 min). The pellet was
resuspended in 2 ml of saline. Cells were counted on Sysmex KX-21
Haematology analyser (Kobe, Japan). Cells were between 78.3 and
92.9% pure (contamination with red and white blood cells).
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2.6. Platelet addition to porcine coronary arteries
Porcine coronary arteries were prepared as previously described. In
some vessels the P2Y14 receptor antagonist PPTN (1 μM) was added
10 min prior to U46619 addition. After a stable tone had been estab-
lished, isolated platelets were added to the vessels; the ﬁnal platelet
concentration in the bath was approximately 24,000–30,000/μL. In
other experiments, L-NAME (100 μM) was added to porcine coronary
arteries and left for 10 min before adding PPTN (1 μM). After pre-
contraction with U46619, the isolated platelets were added.
2.7. Materials
Acetylcholine, apyrase (Grade III), histamine, uridine 5′-dipho-
sphoglucose disodium salt (UDP-glucose), uridine 5′-dipho-
sphoglucuronic acid trisodium salt (UDP-glucuronic acid), uridine 5′-
diphospho-N-acetylglucosamine sodium salt (UDP-N-acet-
ylglucosamine), uridine 5′-triphosphate trisodium salt hydrate (UTP),
7-beta-acetoxy-8,13-epoxy-1-alpha, 6-beta, 9-alpha-trihydroxylabd-14-
en-11-one; coleonol (adenylyl cyclase activator: forskolin), and Nω-
nitro-L-arginine methyl ester hydrochloride (L-NAME) were all ob-
tained from Sigma Aldrich. Diphosphoric acid 1-α-D-glucopyranosyl
ester 2-[(4′-methylthio)uridin-5″-yl] ester disodium salt (MRS2690)
and N,N″-1,4-Butanediylbis[N′-(3-isothiocyanatophenyl)thiourea]
(MRS2578) were obtained from Tocris Biosciences Ltd. PPTN was a gift
from Merck Frosst Centre for Therapeutic Research.
2.8. Statistical analysis
Data were ﬁtted using non-linear regression and statistical analyses
were performed using GraphPad Prism 6.0 software. Rmax is the max-
imal response and logEC50 is the log of the molar concentration of
agonist required to generate 50% of the Rmax. Diﬀerences between Rmax
and logEC50 values were compared using the extra sum of squares F
test, by comparing the extra sum of squares that resulted from the
analysis with separate Rmax or logEC50 values; where out-of-sample
extrapolation occurred all parameters were selected to determine if one
curve adequately ﬁt all data sets (Prism 6). Individual Rmax and logEC50
values were also determined after curve ﬁtting of data for each artery
segment. These parameters were compared using one- or two-way
ANOVA with Tukey's multiple comparisons post hoc test to determine
which groups the diﬀerences were between when> 2 groups were
being compared. Data from VASP-phosphorylation experiments were
analysed using one-way ANOVA with Tukey's post test or Student's t-
test. Data from platelet experiments were analysed by two-way ANOVA
with repeated measures, with Fisher's least signiﬁcant diﬀerence post
hoc test. P < 0.05 was considered statistically signiﬁcant. All data are
presented as mean ± S.E.M. n signiﬁes the number of animals.
3. Results
3.1. P2Y14 receptor agonists constrict coronary arteries
The P2Y14 receptor is activated by various sugar nucleotides, in-
cluding UDP-glucose, UDP-glucuronic acid and UDP-N-acet-
ylglucosamine [4] and, more potently, by the synthetic analogue
MRS2690 [31]. To identify and characterize the P2Y14 receptor in the
porcine coronary artery, cumulative concentration-response curves to
UDP-glucose (0.1 μM-1 mM) and MRS2690 (1 nM-10 μM) were initially
constructed at basal tone. The agonists were found to produce con-
centration-dependent contractions (Fig. 1). MRS2690 was found to be
more potent than UDP-glucose; Rmax and EC50 values are reported in
Table 1. Since the P2Y14 receptor is a Gi/o protein-coupled receptor
mediating inhibition of adenylyl cyclase activity and hence reducing
cAMP production [44–46], arteries were pre-exposed to forskolin to
enhance intracellular cAMP levels prior to constructing the
concentration-response curves. U46619 (5–10 nM), a thromboxane A2
mimetic, was additionally present in these experiments to maintain a
stable basal tone (since forskolin induces vasorelaxation). Under these
conditions, contractile responses to UDP-glucose and MRS2690 were
enhanced as shown in Fig. 1. When the experiment was carried out
using U46619 together with sodium nitroprusside (SNP, activator of
guanylyl cyclase) instead of forskolin, no augmentation of the responses
to UDP-glucose was observed, consistent with a speciﬁc involvement of
cAMP (Fig. 1e). There was a signiﬁcant diﬀerence in the Rmax values for
UDP-glucose between the groups (P < 0.001; extra sum of squares F-
test). Analysis of the data (ANOVA with Tukey's post hoc test) showed
that there was a signiﬁcant increase in the Rmax in the presence of
forskolin plus U46619 (Rmax 1.69 ± 0.24 g, n= 6) compared to the
controls (Rmax 0.35 ± 0.09 g, n = 6; P < 0.001) and compared to the
presence of SNP plus U46619 (Rmax 0.57 ± 0.1 g, n= 12;
P < 0.001). The logEC50 values for UDG-glucose were similar under
the diﬀerent experimental conditions: control −5.4 ± 0.41 (n = 6),
forskolin plus U46619 −4.66 ± 0.14 (n = 6) and SNP plus U466199
−5.03 ± 0.08 (n = 12).
The combination of forskolin plus U46619 failed to augment con-
tractile responses to histamine and acetylcholine (Fig. 2), which cause
vasoconstriction of porcine coronary arteries primarily via Gq/11 cou-
pled H1 histamine receptors [22] and M3 muscarinic receptors [13].
Rmax values for ACh were similar in the absence and presence of for-
skolin plus U46619: 8.94 ± 1.07 g (n= 5) and 9.53 ± 1.13 g (n= 6)
respectively. logEC50 values were also similar in the absence and pre-
sence of forskolin plus U46619: −6.50 ± 0.08 (n = 5) and
−6.57 ± 0.1 (n = 6), respectively (Fig. 2a). Rmax values for histamine
were similar in the absence and presence of forskolin plus U46619:
8.84 ± 0.52 g (n= 4) and 9.71 ± 0.8 g (n = 4), respectively. There
was, however, a small but signiﬁcant diﬀerence in the logEC50 values
for histamine in the presence of forskolin plus U46619 compared to
control conditions:−5.15 ± 0.1 (n = 4) and−5.45 ± 0.07 (n = 4),
respectively (P < 0.01, extra sum of squares F-test) (Fig. 2b), in-
dicating a small reduction in the potency of histamine in the presence of
forskolin plus U46619.
UDP-glucuronic acid and UDP-N-acetylglucosamine (0.1 μM–1 mM)
also produced concentration-dependent contractions of the porcine
coronary arteries (Fig. 3; Table 1). All four of the P2Y14 receptor ago-
nists (UDP-glucose, UDP-glucuronic acid, UDP-N-acetylglucosamine
and MRS2690) produced greater contractions in tissues exposed to
forskolin (and U46619) (Fig. 3b) than in control tissues (Fig. 3a), al-
though analysis of the Rmax values showed that this diﬀerence was only
statistically signiﬁcant for UDP-glucose and UDP-glucuronic acid
(ANOVA, Table 1). An increase in contractility under these experi-
mental conditions is consistent with an involvement of Gi/o protein
coupled receptors and inhibition of cAMP. There was a signiﬁcant dif-
ference between the logEC50 values of the agonists (P < 0.001), but
their Rmax values were similar (P > 0.05) (extra sum of squares F-test).
Analysis of the logEC50 values (ANOVA with Tukey's post test) showed
that MRS2690 was signiﬁcantly more potent than the other UDP-sugars
(Table 1). UMP (0.1 μM−1 mM) did not cause contraction of the
porcine coronary arteries (tested in the presence of forskolin and
U46619; data not shown).
Removal of the endothelium had no signiﬁcant eﬀect on the con-
tractile response to UDP-glucose in the porcine coronary artery,
showing that this was mediated by direct actions on the smooth muscle
(Fig. 4a); Rmax values were 2.96 ± 0.22 g (n= 12) and 3.12 ± 0.36 g
(n= 11) in endothelium-intact and -denuded arteries, respectively, and
logEC50 values were −4.25 ± 0.13 (n = 12) and −4.34 ± 0.14
(n = 11), respectively. Substance P (10 nM) was used to conﬁrm the
presence of the endothelium in the porcine coronary arteries: in en-
dothelium-intact arteries relaxation was 41 ± 6.4% (n = 12); in en-
dothelium-denuded arteries substance P did not cause a relaxation
(n = 11).
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3.2. Eﬀects of suramin and PPADS, P2 receptor antagonists, on contractile
responses to UDP-glucose in coronary arteries
The P2 receptor antagonist suramin (100 μM) reduced the maximal
contractile response to UDP-glucose (obtained in the presence of
forskolin plus U46619) from 2.94 ± 0.45 g (n= 7) to 2.12 ± 0.29 g
(n= 8) (P < 0.01, extra sum of squares F test) (Fig. 4b). The logEC50
values were not signiﬁcantly diﬀerent at −4.74 ± 0.04 (n= 7) and
−4.50 ± 0.07 (n = 8), in the absence and presence of suramin re-
spectively. These data are consistent with an involvement of P2 receptors
Table 1
Contractile responses of the porcine coronary artery to UDP-sugars. Shown are the EC50 (− log M) and Rmax values.
Agonist EC50 ± S.E.M (− log M) Rmax ± S.E.M (contraction in g)
Control Forskolin (+U46619) Control Forskolin (+U46619)
UDP-glucose 4.89 ± 0.21
n = 12
4.66 ± 0.14
n = 6
0.37 ± 0.06 1.69 ± 0.24#
UDP-glucuronic acid 4.80 ± 0.27
n= 7
3.63 ± 0.21
n = 7
0.42 ± 0.04 2.26 ± 0.51###
UDP-N-acetylglucosamine 4.86 ± 0.23
n = 7
4.27 ± 0.11
n = 7
0.49 ± 0.10 1.72 ± 0.31
MRS2690 6.30 ± 0.45**
n= 4
5.71 ± 0.16ϕ
n= 12
0.48 ± 0.14 1.77 ± 0.32
Contractile response curves were investigated in arteries under control conditions (Control) and in arteries to which forskolin had been added to stimulate adenylyl cyclase (with U46619
added to maintain a stable tone; see Methods) (forskolin). **P < 0.01 for MRS2690 −logEC50 compared with -logEC50s of UDP-glucose, UDP-glucuronic acid and UDP-N-acet-
ylglucosamine in controls (two way ANOVA with Tukey's post test). ϕ P < 0.05, P < 0.001, P < 0.001 for MRS2690 -logEC50 compared with -logEC50s of UDP-glucose, UDP-
glucuronic acid and UDP-N-acetylglucosamine respectively, in the presence of forskolin (two-way ANOVA with Tukey's post test). Agonist Rmax values in the presence of forskolin were
signiﬁcantly greater compared to corresponding Rmax values obtained under control conditions for both UDP-glucose and UDP-glucuronic acid; #P < 0.5, ###P < 0.001 (two-way
ANOVA with Tukey's post test). Data are mean ± S.E.M.
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Fig. 1. UDP-glucose and the selective P2Y14 receptor ago-
nist MRS2690 mediate contraction of porcine coronary
arteries. Representative traces showing concentration-de-
pendent contractile responses of porcine coronary arteries
to UDP-glucose (a, c) and MRS2690 (b, d) at basal tone in
the absence (Control) and presence of forskolin (0.1 μM)
plus U46619. Lines on traces represent addition of cumu-
lative concentrations of agonists. The mean data ± S.E.M.
are of experiments from 6 to 12 diﬀerent pigs (e, f). For
UDP-glucose (e) the Rmax was signiﬁcantly diﬀerent be-
tween the groups (P < 0.001, extra sum of squares F test)
with no diﬀerence in logEC50values. For MRS2690 (f) the
curves were signiﬁcantly diﬀerent (P < 0.001, extra sum
of squares F test).
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as mediators of the contractile response to UDP-glucose, but do not in-
dicate which P2 receptor subtype(s) are involved. In contrast, PPADS
(10 μM) augmented the contractile response to UDP-glucose (obtained in
the presence of forskolin plus U46619) (Fig. 4c); the Rmax was sig-
niﬁcantly greater in the presence of PPADS at 2.42 ± 0.23 g (n= 6)
than in the control at 2.03 ± 0.16 g (n= 6) (P < 0.01, extra sum of
squares F test) and the sensitivity of the response to UDP-glucose was
also increased in the presence of PPADS, logEC50 =−5.77 ± 0.05
(n = 6) compared to the control, logEC50 =−4.81 ± 0.08 (n = 6)
(P < 0.001, extra sum of squares F test).
3.3. PPTN, a selective P2Y14 receptor antagonist, blocks responses to
MRS2690, a selective P2Y14 receptor agonist, in coronary arteries
In order to investigate the possible involvement of the P2Y14 re-
ceptor in the porcine coronary artery, PPTN was used to examine
contractile responses to the P2Y14 receptor agonists UDP-glucose and
MRS2690. PPTN at 1 μM acts selectively to inhibit the P2Y14 receptor
with no eﬀect at the other P2Y receptor subtypes [6]. In the presence of
PPTN (1 μM), the contractile responses to UDP-glucose were attenuated
and there was a signiﬁcant diﬀerence between the response curves
(P < 0.01, extra sum of squares F-test) (Fig. 5a). The contractions to
MRS290 were also attenuated by PPTN with a signiﬁcant diﬀerence
between the response curves (P < 0.001, extra sum of squares F-test)
(Fig. 5b).
UTP is an agonist at P2Y2 and P2Y4 receptors, and elicits contraction
of porcine coronary arteries through activation of these receptors [41].
UTP does not have any eﬀect at the P2Y14 receptor [9]. To determine
the selectivity of action of PPTN versus other P2Y receptors in the PCA,
namely P2Y2 and P2Y4 receptors, the eﬀect of PPTN on contractile re-
sponses to UTP was investigated. PPTN had no signiﬁcant eﬀect on the
contractile responses to UTP (Fig. 5c).
3.4. MRS2578, a selective P2Y6 receptor antagonist, does not block
responses to MRS2690 and UDP-glucose in coronary arteries
P2Y6 receptors are present in the porcine coronary artery and, upon
activation by their endogenous ligand UDP, elicit vasoconstriction [41].
We investigated whether UDP-glucose and MRS2690 cause a P2Y6 re-
ceptor mediated contractile response in porcine coronary arteries. In
addition, in order to determine whether the contractions to UDP-glu-
cose involved UDP, either present as a contaminant or following release
from the tissue, the UDP-glucose solution was treated with the nu-
cleotidase apyrase (5 U/ml, 30 min) and apyrase was also added to the
organ baths (5 U/ml, prior to addition of forskolin and U46619). We
found that neither MRS2578 (10 μM), a selective P2Y6 receptor
-9 -8 -7 -6 -5
0
2
4
6
8
10 Forskolin + U46619
Control
n=5-7
log [ACh] M
co
n
tr
ac
ti
o
n
(g
)
-9 -8 -7 -6 -5 -4 -3
0
2
4
6
8
10 Forskolin + U46619
Control
n=4
log [Histamine] M
co
n
tr
ac
ti
o
n
(g
)
a
b
Fig. 2. Forskolin plus U46619 do not augment contractions to acetylcholine and hista-
mine in porcine coronary arteries. Cumulative concentration-response curves to acet-
ylcholine (ACh) (a) and histamine (b), under control conditions and the eﬀect of forskolin
(0.1 μM) plus U46619. There was no signiﬁcant diﬀerence in the Rmax values for either
compound, or in the logEC50 values for ACh, but there was a small but signiﬁcant dif-
ference in logEC50 values for histamine, indicating a slightly reduced potency in the
presence of forskolin plus U46619 (P < 0.01, extra sum of squares F-test). Data are
mean ± S.E.M.
a
b
Control
Forskolin plus U46619
log [agonist] M
co
n
tr
ac
ti
o
n
(g
)
-10 -8 -6 -4 -2
0.0
0.2
0.4
0.6
0.8
UDP-glucose
UDP-glucuronic acid
UDP-N-acetylglucosamine
n= 4-12
MRS2690
-10 -8 -6 -4 -2
0.0
0.5
1.0
1.5
2.0
2.5 UDP-glucuronic acid
UDP-N-acetylglucosamine
log [agonist] M
co
n
tr
ac
ti
o
n
(g
)
UDP-glucose
MRS2690
n=6-12
Fig. 3. UDP-sugars mediate contraction of porcine coronary arteries and the responses are
augmented by forskolin. Cumulative concentration-response curves to P2Y14 receptor
agonists in the porcine coronary artery. UDP-glucose, UDP-glucuronic acid, UDP-N-
acetylglucosamine and the P2Y14 receptor agonist MRS2690 were investigated in isolated
porcine coronary arteries under control conditions (a) and in arteries to which forskolin
(0.1 μM) and U46619 had been added to elevate cAMP and maintain tone, respectively
(b). Note the diﬀerent y axes scales in panels a and b. There was a signiﬁcant diﬀerence in
the agonist logEC50 values in the presence of forskolin plus U46619 (P < 0.001, extra
sum of squares F test) (see also Table 1). Data are mean ± S.E.M.
Z.S.B. Abbas et al. Vascular Pharmacology xxx (xxxx) xxx–xxx
5
antagonist, nor apyrase, had any signiﬁcant eﬀect on contractile re-
sponses induced by UDP-glucose, in coronary arteries in the presence of
forskolin and U46619 (Fig. 6a). UDP-glucose Rmax values were:
2.93 ± 0.49 g (n= 7), 2.92 ± 0.70 g (n= 6), 2.68 ± 0.46 g
(n = 6) and 2.81 ± 0.54 g (n= 5), in controls and in the presence of
MRS2578, apyrase and MRS2578 plus apyrase, respectively; the cor-
responding logEC50 values were −5.26 ± 0.11, −5.45 ± 0.28,
−5.48 ± 0.16, and −5.58 ± 0.16. MRS2578 also had no signiﬁcant
eﬀect on contractions mediated by MRS2690 in coronary arteries in the
presence of forskolin and U46619, in line with the selectivity of this
compound for P2Y14 receptors; Rmax values were 3.38 ± 0.66 g
(n= 8) in controls and 2.71 ± 0.54 g (n= 10) in the presence of
MRS2578 and the corresponding logEC50 values were −6.76 ± 0.22
and −6.70 ± 0.13 (Fig. 6b).
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3.5. P2Y14 receptor agonists decrease VASP-phosphorylation in coronary
arteries
Increases in intracellular cAMP levels lead to the phosphorylation of
vasodilator-stimulated phosphoprotein (VASP) via cAMP-dependent
protein kinase A (PKA) and other kinases. Thus VASP-phosphorylation
(VASP-P) can be used to measure levels of cAMP. In the present study,
forskolin was used to increase cAMP levels in porcine coronary arteries.
Forskolin alone (0.1 μM), an activator of adenylate cyclase, sig-
niﬁcantly increased VASP-P levels (P < 0.001, ANOVA with Tukey's
post test) (Fig. 7a). UDP-glucose (100 μM) and MRS2690 (10 μM) sig-
niﬁcantly decreased the forskolin-elevated levels of VASP-P, to levels
that were similar to those measured in control tissues (P < 0.05,
ANOVA with Tukey's post test) (Fig. 6a). PPTN (1 μM) was able to
partially restore levels of VASP-P that were decreased by UDP-glucose
and MRS2690 in porcine coronary arteries (Fig. 7b). PPTN alone (1 μM)
had no signiﬁcant eﬀect on VASP-P levels in forskolin exposed porcine
coronary arteries (Fig. 7c). Together these results suggest that P2Y14
receptor activation couples to the inhibition of adenylate cyclase ac-
tivity, hence reducing levels of cAMP and VASP-P in porcine coronary
arteries in vitro.
3.6. Eﬀect of platelets in porcine coronary arteries and the eﬀect of PPTN
Isolated platelets (24,700–30,000 cells/μl) added to coronary artery
segments that had been preconstricted with U46619 caused a sig-
niﬁcant relaxation (P < 0.01, two-way ANOVA) which reversed over
time (Fig. 8a–c). PPTN (1 μM) did not signiﬁcantly change the mean
relaxation response induced by the platelets from 3 donors (Fig. 8a–c).
L-NAME (100 μM), a nitric oxide synthase inhibitor, was added to
vessels to remove the platelet-induced relaxations, and in its presence
platelets caused predominantly contraction (P < 0.001, two-way
ANOVA) (Fig. 8d-g). PPTN had no signiﬁcant eﬀect on the mean pla-
telet-induced contractions in the presence of L-NAME in 3 donors
(Fig. 8e–g), although for one donor the platelet-induced contractile
response was augmented (two-way ANOVA) (Fig. 8d).
4. Discussion
We have provided the ﬁrst evidence for the functional expression of
the P2Y14 purine receptor in the porcine coronary vasculature.
Vasoconstriction was produced by UDP-glucose, UDP-glucuronic acid,
UDP-N-acetylglucosamine and MRS2690, all of which are known P2Y14
receptor agonists [4,9], and MRS2690 was more potent than the UDP-
sugars, consistent with previous characterization of MRS2690 as a po-
tent and selective P2Y14 receptor agonist [31]. Responses to UDP-glu-
cose and MRS2690 were selectively antagonized by PPTN, a competi-
tive antagonist at the P2Y14 receptor [6,43], but were unaﬀected by the
P2Y6 receptor antagonist MRS2578.
Forskolin is routinely added to cultured and dissociated cells to
elevate cAMP levels in order to reveal the function of Gi/o protein-
coupled receptors, and although less commonly used in intact tissue it
has been used to uncover vasocontractile α2-adrenoceptors in the por-
cine ear artery [42] and P2Y14 receptors in the porcine pancreatic ar-
tery [5]. Vasocontractile responses to the endogenous and synthetic
P2Y14 receptor agonists were increased in vessels in the presence of
forskolin, but not when the forskolin was substituted with sodium ni-
troprusside (increases cGMP). Moreover, the combination of U46619
and forskolin had no eﬀect on contractions to histamine and acet-
ylcholine, which in porcine coronary arteries are mediated through
activation of H1 histamine receptors [22] and M3 muscarinic receptors
[13] respectively; both receptors are coupled to Gq/11 proteins and
therefore do not inhibit adenylyl cyclase activity, suggesting that for-
skolin treatment was not augmenting responses to the vasoconstrictors
non-selectively. These observations are consistent with the involvement
of Gi/o protein-coupled P2Y14 receptors causing inhibition of adenylyl
cyclase activity and a reduction in cAMP. Pertussis toxin treatment
(which blocks Gi/o protein-coupling) inhibits UDP-glucose binding to
P2Y14 receptors [4,9], but we were not able to use pertussis toxin
successfully in our studies, possibly because of diﬃculties with it per-
meating the multilayered tissue. Physiologically, elevations in cAMP
levels might occur following activation of Gs protein-coupled β-adre-
noceptors and A2A and A2B adenosine receptors and concomitant UDP-
sugar activation of P2Y14 receptors would be expected to limit vaso-
dilatation, and other functions, mediated by these receptors.
The selective P2Y14 receptor agonist MRS2690 was more potent
than UDP-glucose, UDP-glucuronic acid and UDP-N-acetylglucosamine,
consistent with the literature [16,28]. Contractions to MRS2690 were
evident at concentrations equal to and below 10 μM, and at 10 μM
MRS2690 is inactive at P2Y2 receptors [30]. PPTN, which inhibits
P2Y14 receptors but not other P2Y receptors [6,43], blocked contractile
responses of the porcine coronary artery to MRS2690 and the responses
were virtually abolished at 1 μM MRS2690. Contractile responses to
UTP (agonist at P2Y2 and P2Y4 receptors) were unaﬀected by PPTN at a
concentration that inhibited responses to MRS2690. Moreover, the
contractile response to MRS2690 was unaﬀected by the P2Y6 receptor
antagonist MRS2578 [37]. These results indicate that P2Y14 receptors
are functionally expressed in porcine coronary arteries, along with
P2Y2, P2Y4 and P2Y6 receptors, for which the principal endogenous
ligands are UTP and ATP (P2Y2), UTP (P2Y4) and UDP (P2Y6) [41].
With regard to the endogenous ligands, contractile responses to
UDP-glucose were mimicked by UDP-glucuronic acid and UDP-N-acet-
ylglucosamine, consistent with an involvement of P2Y14 receptors. This
is unlike UDP-glucose responses in N9 microglia which were not mi-
micked by UDP-galactose and thus were suggested to be independent of
P2Y14 receptors [7]. Moreover, responses to UDP-glucose were blocked
by PPTN, indicating actions at P2Y14 receptors, and consistent with a
role for UDP sugars as extracellular signalling molecules. Contractile
-8 -7 -6 -5 -4 -3 -2
0
1
2
3
4
log [UDP-glucose] M
Co
n
tr
ac
tio
n
(g
)
Control
MRS2578 (10 µM)
n=5-6
*
apyrase (5 U/ml)
MRS2578 (10 µM) + apyrase (5 U/ml)
-10 -9 -8 -7 -6 -5 -4
0
1
2
3
4
5
log [MRS2690] M
Co
nt
ra
c
tio
n
(g
)
Control
MRS2578 (10 µM)
n=8-10
a b Fig. 6. Contractile responses to UDP-glucose and MRS2690are unaﬀected by the selective P2Y6 receptor antagonist
MRS2578. Eﬀect of MRS2578, on concentration-response
curves to (a) UDP-glucose and (b) MRS2690 in porcine
coronary arteries. UDP-glucose and MRS260 caused con-
centration-dependent contractions in the presence of for-
skolin and U46619. Contractions to UDP-glucose were
unaﬀected by MRS2578 or by prior incubation of the UDP-
glucose solution and tissues with apyrase (5 U/ml,> 30
min) (a). Contractions to MRS2690 were also unaﬀected by
MRS2578. Data are mean ± S.E.M.
Z.S.B. Abbas et al. Vascular Pharmacology xxx (xxxx) xxx–xxx
7
responses to UDP-glucose were also attenuated by the non-selective P2
receptor antagonist suramin. The non-selective P2 receptor antagonist
PPADS augmented contractile responses to UDP-glucose, as reported by
us previously in porcine pancreatic arteries [5]; the mechanism remains
to be determined but does not appear to involve the ectonucleotidase
inhibitory activity of PPADS [10,20] and potentiation of responses to
contaminant nucleotides, since our experiments with apyrase indicate
that nucleotides are not present as major contaminants of UDP-glucose,
as reported by others [47]. There is evidence for interactions between
cAMP and Ca2+ signalling pathways such that an increase in in-
tracellular Ca2+ inhibits cAMP accumulation [11]. There is also evi-
dence that PPADS antagonises IP3-induced intracellular Ca2+ mobili-
zation [50] and that it elevates basal cAMP levels [40]. Thus, it is
possible that a PPADS-induced elevation of cAMP levels (further to the
elevation caused by forskolin), possibly involving a reduction in in-
tracellular Ca2+, leads to its facilitation of contractile responses to
UDP-glucose.
Actions at multiple P2Y receptor targets is common among purine/
pyrimidine nucleotides [8] but responses to UDP-glucose were not in-
hibited by MRS2578 indicating a lack of involvement of vasocontractile
P2Y6 receptors [41]. Another possible target is the P2Y2 receptor, at
which UDP-glucose is known to act, albeit weakly [30], and which is
present in the porcine coronary artery [41]. In coronary and basilar
arteries from P2Y2 knockout mice the response to UDP-glucose was
slightly, but not signiﬁcantly, smaller than that in arteries from wild
type mice [21]. UMP and uridine are known not to contribute to P2Y14
receptor activation [9], and we found that UMP did not contract por-
cine coronary arteries (unpublished observations).
Since endothelium removal had no eﬀect on contractions to UDP-
glucose, the P2Y14 receptors mediating this response are likely to be
located on the coronary artery smooth muscle. We have shown that the
P2Y14 receptor is located on both the smooth muscle and endothelium
of porcine pancreatic arteries [5], reinforcing that P2 receptor expres-
sion can vary with blood vessel as well as species [8]. Expression of
mRNA encoding P2Y14 was shown in rat and mouse aortic smooth
muscle [19,29]. Meister et al. [38] also reported P2Y14 expression in
blood vessels, but mainly in veins. In immunoblotting experiments for
P2Y14 receptor protein we showed a band at 41 kDa, which is close to
the predicted molecular weight of 38 kDa for the P2Y14 receptor, and an
additional, stronger band was seen at 61 kDa (Supplemental data). Si-
milar sized bands (34 kDa and 56 kDa) were reported for P2Y14 in C6
glioma cells, and evidence was provided of a contribution of glycosy-
lation to the higher molecular weight band [33]. However, the speci-
ﬁcity of commercially available antibodies is a concern (see [18]) and
validation of the P2Y14 receptor antibody is needed to understand
whether these bands are the P2Y14 receptor.
In parallel studies, VASP-P was measured as an indicator of cAMP
accumulation in the porcine coronary artery. Forskolin signiﬁcantly
enhanced VASP-P, and UDP-glucose and MRS2690 inhibited the for-
skolin-induced increase in VASP-P. Moreover PPTN was able to par-
tially reverse the UDP-glucose and MRS2690 mediated inhibition of
forskolin-induced VASP-P, consistent with an involvement of P2Y14
receptors mediating a reduction in cAMP levels. PPTN was similarly
shown to antagonise UDP-glucose-mediated inhibition of adenylyl cy-
clase activity in C6 glioma cells expressing P2Y14 receptors [6]. UDP-
glucose also inhibited forskolin-stimulated cAMP accumulation in T-
lymphocytes, neutrophils and human astrocytoma cells [44–46].
Overall, the data suggest that as in other tissues, the P2Y14 receptor in
the porcine coronary artery is Gi/o protein-coupled.
The present ﬁndings are important because there is evidence that
UDP-glucose may be a more stable extracellular signalling molecule
than ATP and UTP, both of which have been shown to be released from
heart during coronary hypoxia/ischaemia [14,15,24]. Release of UDP-
glucose has been shown from several cell types (including human as-
trocytoma cells, Calu-3 airway epithelial cells, COS-7, CHO-K1 and C6
glioma cells) and, signiﬁcantly, unlike ATP levels, the stimulated levels
of UDP-glucose remained elevated for up to 3 h [36]. Similarly, there
was negligible metabolism of extracellular UDP-glucose in neutrophil
suspensions at 1 h, at which time ATP had been completely hydrolysed
by neutrophil NTPDase1 (nucleotide triphosphate diphosphohydrolase-
1), which hydrolyses extracellular nucleotides but not UDP-sugars [47].
This has important implications for P2Y14 receptor signalling during
cardiac hypoxia, ischaemia, inﬂammation, or cell damage, during
which UDP-glucose may be released within the coronary vasculature.
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Fig. 7. UDP-glucose-induced VASP-phosphorylation is blocked by the P2Y14 receptor
antagonist PPTN. Levels of VASP phosphorylation (VASP-P) in porcine coronary arteries
at basal tone, in the absence (Control) and presence of forskolin and the eﬀect of UDP-
glucose (UDPG), MRS2690 (P2Y14 receptor agonist) and PPTN (P2Y14 receptor antago-
nist). (a) Levels of VASP-P in control conditions and in the presence of forskolin, forskolin
+ UDP-glucose (100 μM), and forskolin + MRS2690 (10 μM). (b) Eﬀect of UDP-glucose
(1 mM) and MRS2690 (10 μM) on forskolin-induced VASP phosphorylation in porcine
coronary arteries in the absence and presence of PPTN (1 μM). (c) Eﬀect of PPTN (1 μM)
on forskolin-induced VASP-P. VASP-phosphorylation was measured using ﬂow cytometry.
*P < 0.05, **P < 0.01; ***P < 0.001, ANOVA with Tukey's post test. PPTN alone had
no eﬀect on VASP-P (Student's t-test). Data are mean ± S.E.M.
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UDP-glucose levels of ~90 μM were determined in heart extracts [34]
and are in line with the eﬀective concentrations of UDP-glucose pro-
ducing vasocontraction of the coronary arteries in the present study.
Such levels might be found following exocytotic release of UDP-glucose
or upon cell damage in the heart or following hypoxia, ischaemia or
inﬂammation. Other potential sources of UDP-sugars in the cardiovas-
cular system include platelets, leukocytes and endothelial cells. It fol-
lows that antagonists at P2Y14 receptors may have therapeutic potential
in ischaemic heart disease.
UDP-sugars including UDP-glucose, UDP-galactose, UDP-glucuronic
acid and UDP-N-acetylglucosamine have been measured in platelets
[51] and we were interested to see if UDP-sugars are released from
activated platelets to mediate contraction of coronary arteries. In the
porcine coronary arteries the addition of platelets from the human
donors produced a relaxation, which was unaﬀected by PPTN. In canine
coronary arteries, aggregating platelets cause an endothelium-depen-
dent relaxation which is largely due to the actions of ADP and ATP
released from the platelets and this relaxation was reduced in vessels
treated with apyrase [25,26]. In endothelium denuded canine coronary
arteries, platelets elicit vasoconstriction that does not occur in en-
dothelium intact vessels [26,48]. Thus, we used an inhibitor of nitric
oxide synthase, L-NAME, to uncover the contractile response to the
platelets. This is the ﬁrst study to use L-NAME to block platelet-induced
relaxations in vascular tissue and thus to show a speciﬁc involvement of
NO. The porcine coronary arteries contracted when platelets were
added in the presence of L-NAME, likely due to actions of contractile
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Fig. 8. Eﬀect of platelets and the P2Y14 receptor antagonist
PPTN, on porcine coronary artery contractility. Platelets
isolated from 7 healthy adult human donors were added to
U46619-preconstricted porcine coronary arteries in the
absence (a–c) and presence (d–g) of L-NAME (100 μM), a
nitric oxide synthase inhibitor, in the absence and presence
of PPTN (1 μM) (P2Y14 receptor antagonist). In the absence
of L-NAME the platelets elicited vasorelaxation. In the
presence of L-NAME platelets elicited vasoconstriction. n
indicates the number of diﬀerent pigs from which coronary
artery segments were obtained. *P < 0.05; **P < 0.01
for comparison of responses in the absence and presence of
PPTN (two way ANOVA). Data are mean ± S.E.M.
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mediators including 5-HT and thromboxane A2 released from the acti-
vated platelets [26], but PPTN had no signiﬁcant eﬀect on this response
in 3 of the donors and augmented the response in one, suggesting that
P2Y14 receptors do not contribute signiﬁcantly under the conditions of
the present study. The eﬀects of the UDP-sugars may be small in
comparison to those of the other components released from platelets.
High levels of P2Y14 receptor mRNA have been detected in mega-
karyocytic cells and platelets [39]. Although P2Y14 receptors have been
characterised in platelets using immunoblotting analysis, UDP-glucose
and MRS2690 did not have any eﬀect on a number of human platelet
functions [12].
In summary, UDP-glucose mediates contraction of the porcine cor-
onary artery via P2Y14 receptors. The P2Y14 receptor is coupled nega-
tively to adenylyl cyclase since UDP-glucose and the selective P2Y14
receptor agonist MRS2690 decreased cAMP accumulation as de-
termined by lower levels of VASP-P; these decreased levels of VASP-P
could partially be restored by PPTN, a selective P2Y14 receptor an-
tagonist. P2Y14 receptors may be involved in the control of coronary
arterial blood ﬂow and may, therefore, be possible targets for the
treatment of ischaemic heart disease.
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